MRNA - Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest
- Arbutus expects to have data readouts from three phase 2 triple combination studies using AB-729 for Hepatitis B in the 2nd half of 2022.
- Results from the phase 1a/1b study using AB-729 for Hep B from multiple cohorts are expected at a medical conference in 2022.
- Results from the phase 1 study using AB-836 for the treatment of patients with Hepatitis B are expected in the 1st half of 2022.
- Patent litigation against Moderna for patent infringement dealing with its Covid-19 vaccine may possibly bring in revenue for Arbutus/Genevant should a deal be reached or successful litigation in court.
For further details see:
Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest